Nuformix PLC Result of AGM (3005B)

TIDMNFX

RNS Number : 3005B

Nuformix PLC

19 September 2018

Nuformix plc

Result of Annual General Meeting

The Annual General Meeting of Nuformix plc was held on 19(th) September 2018 at 1.00pm, at the offices of Shakespeare Martineau LLP, 60 Gracechurch Street, London, EC3V 0HR.

The Directors of the Company wish to announce that all the resolutions were passed by the required majority. The results of the voting by poll on the resolutions put to the meeting are listed below.

 
                  Resolution               Ordinary/      For*                Against              Total 
                                            Special                                                votes 
                                                                                                    cast 
                                                         No. of        %      No. of      % 
                                                          votes                votes 
      To receive the annual 
       report and accounts 
       for the year ended 
 1     31 March 2018                       Ordinary    141,656,903    100        0        0     141,656,903 
      To approve the Directors' 
 2     Remuneration Policy                 Ordinary    134,767,823   95.14   6,889,080   4.86   141,656,903 
      To approve the Annual 
 3     Report on Remuneration              Ordinary    134,767,823   95.14   6,889,080   4.86   141,656,903 
      To re-appoint David 
 4     Tapolczay as a director             Ordinary    141,656,903    100        0        0     141,656,903 
      To re-appoint Daniel 
 5     Gooding as a director               Ordinary    134,767,823   95.14   6,889,080   4.86   141,656,903 
      To re-appoint Joanne 
 6     Holland as a director               Ordinary    141,656,903    100        0        0     141,656,903 
      To re-appoint John 
 7     Lidgey as a director                Ordinary    141,656,903    100        0        0     141,656,903 
      To re-appoint Kirk 
       Siderman-Wolter 
 8     as a director                       Ordinary    141,656,903    100        0        0     141,656,903 
      To re-Christopher 
 9     Blackwell as a director             Ordinary    141,656,903    100        0        0     141,656,903 
      To re-appoint haysmacintyre 
 10    as auditor                          Ordinary    141,656,903    100        0        0     141,656,903 
                 To authorise the 
                  Directors to determine 
 11               the auditor's fees.      Ordinary    134,767,823   95.14   6,889,080   4.86   141,656,903 
      To authorise the 
       Directors to allot 
 12    shares.                             Ordinary    134,767,823   95.14   6,889,080   4.86   141,656,903 
                 To authorise the 
                  Directors to disapply 
 13               pre-emption rights.       Special    134,767,823   95.14   6,889,080   4.86   141,656,903 
                 To authorise the 
                  Company to purchase 
 14               its own shares.           Special    134,767,823   95.14   6,889,080   4.86   141,656,903 
          To authorise calling 
           of a general meeting 
           on 14 clear days' 
 15        notice.                          Special    134,767,823   95.14   6,889,080   4.86   141,656,903 
 

*The 'For' votes include those votes giving the Chairman discretion.

A vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.

The Company's issued share capital is 460,750,000 ordinary shares of 0.1p each.

Copies of the resolutions passed as special resolutions at the AGM will shortly be available for inspection at the National Storage Mechanism, which is located at: http://www.morningstar.co.uk/uk/nsm.

19 September 2018

For further information please contact:

 
 Nuformix plc 
  Dr Dan Gooding, Chief Executive Officer   [phone] 
 Gable Communications Ltd 
  John Bick / Justine James                 [phone] 
 

About Nuformix plc www.nuformix.com

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.

Nuformix has created an IP portfolio containing a range of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

Nuformix was established in Cambridge in 2009 and has invested into pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities. Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

RAGXKLFFVKFXBBF

(END) Dow Jones Newswires

September 19, 2018 09:33 ET (13:33 GMT)